ATE327225T1 - Neue verwendung von benzothiazolderivaten - Google Patents

Neue verwendung von benzothiazolderivaten

Info

Publication number
ATE327225T1
ATE327225T1 AT03788208T AT03788208T ATE327225T1 AT E327225 T1 ATE327225 T1 AT E327225T1 AT 03788208 T AT03788208 T AT 03788208T AT 03788208 T AT03788208 T AT 03788208T AT E327225 T1 ATE327225 T1 AT E327225T1
Authority
AT
Austria
Prior art keywords
sub
new use
benzothiazole derivatives
formula
disclosed
Prior art date
Application number
AT03788208T
Other languages
English (en)
Inventor
Peter Sjoe
Peter Storm
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE327225T1 publication Critical patent/ATE327225T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/64Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT03788208T 2002-08-14 2003-08-13 Neue verwendung von benzothiazolderivaten ATE327225T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0202429A SE0202429D0 (sv) 2002-08-14 2002-08-14 Novel Compounds

Publications (1)

Publication Number Publication Date
ATE327225T1 true ATE327225T1 (de) 2006-06-15

Family

ID=20288724

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03788208T ATE327225T1 (de) 2002-08-14 2003-08-13 Neue verwendung von benzothiazolderivaten

Country Status (16)

Country Link
US (1) US20060106015A1 (de)
EP (1) EP1539723B1 (de)
JP (1) JP2006504672A (de)
KR (1) KR20060002728A (de)
CN (1) CN1675189A (de)
AT (1) ATE327225T1 (de)
AU (1) AU2003248587A1 (de)
BR (1) BR0313407A (de)
CA (1) CA2495492A1 (de)
DE (1) DE60305514D1 (de)
IL (1) IL166412A0 (de)
MX (1) MXPA05001585A (de)
NO (1) NO20051263L (de)
SE (1) SE0202429D0 (de)
WO (1) WO2004016600A1 (de)
ZA (1) ZA200501098B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101044126A (zh) * 2004-08-26 2007-09-26 惠氏公司 作为雌激素药物的前药取代的苯并唑化合物
NZ560969A (en) 2005-02-17 2010-08-27 Albany Molecular Res Inc Benzoxazole carboxamides for treating chemotherapy-induced vomiting and irritable bowel syndrome
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
EP1910385B1 (de) 2005-08-04 2013-07-24 Sirtris Pharmaceuticals, Inc. Benzothiazole und thiazolopyridine als sirtuinmodulatoren
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
DK1990330T3 (da) * 2007-05-07 2011-09-26 Siemens Ag Keramisk pulver, keramisk lag og lagsystem med pyrochlorfase og oxider
TW200916472A (en) 2007-06-20 2009-04-16 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
ATE523508T1 (de) 2007-10-25 2011-09-15 Astrazeneca Ab Für die behandlung von zellproliferativen erkrankungen geeignete pyridin- und pyrazinderivate
EP2376502B1 (de) 2008-12-19 2015-06-17 GlaxoSmithKline LLC Thiazolopyridin-sirtuin-modulierende verbindungen
WO2013153539A1 (en) 2012-04-13 2013-10-17 Glenmark Pharmaceuticals S.A. Tricyclic compounds as tec kinase inhibitors
US9795604B2 (en) 2013-10-25 2017-10-24 Pharmacyclics Llc Methods of treating and preventing graft versus host disease
MX383691B (es) 2015-03-06 2025-03-14 Beyondspring Pharmaceuticals Inc Método de tratamiento de cáncer asociado con una mutación de ras.
AU2016317049A1 (en) 2015-08-31 2018-03-15 Pharmacyclics Llc BTK inhibitor combinations for treating multiple myeloma
WO2017139231A1 (en) 2016-02-08 2017-08-17 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
RU2760348C2 (ru) 2016-06-06 2021-11-24 Бейондспринг Фармасьютикалс, Инк. Способ уменьшения нейтропении
AU2017355544A1 (en) 2016-11-03 2019-05-16 Juno Therapeutics, Inc. Combination therapy of a T cell therapy and a BTK inhibitor
KR102279347B1 (ko) 2016-12-15 2021-07-21 한국생명공학연구원 피리딘계 화합물을 유효성분으로 함유하는 dyrk 관련 질환의 예방 또는 치료용 약학적 조성물
WO2018111049A1 (ko) * 2016-12-15 2018-06-21 한국생명공학연구원 피리딘계 화합물을 유효성분으로 함유하는 dyrk 관련 질환의 예방 또는 치료용 약학적 조성물
JP2020503363A (ja) 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド チューブリン結合化合物およびその治療的使用
BR112019015974A2 (pt) 2017-02-01 2020-03-31 Beyondspring Pharmaceuticals, Inc. Método para reduzir neutropenia
KR20200112881A (ko) 2018-01-24 2020-10-05 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법
BR112020018094A2 (pt) 2018-03-08 2020-12-22 Incyte Corporation Compostos de aminopirazina diol como inibidores de pi3k-¿
US20210121466A1 (en) 2018-05-03 2021-04-29 Juno Therapeutics, Inc. Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
CN112778155B (zh) * 2019-11-11 2023-08-11 大连万春布林医药有限公司 妥卡雷琐衍生物及其用途
CA3215047A1 (en) 2021-04-09 2022-10-13 Lan Huang Therapeutic compositions and methods for treating tumors
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2025188028A1 (ko) * 2024-03-05 2025-09-12 한국생명공학연구원 피리딘계 화합물을 유효성분으로 함유하는 염증성 질환 또는 자가면역질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL242547A (de) * 1958-08-22
DE2145178C3 (de) * 1970-09-11 1975-12-11 Tokyo Tanabe Co., Ltd., Tokio 2-Phenyl-5-oder -6-benzothiazolylessigsäure-Verblndungen
JPS4932855B1 (de) * 1971-08-03 1974-09-03
DD150059A1 (de) * 1980-04-07 1981-08-12 Horst Hartmann Verfahren zur herstellung von hydroxyarylazolen
JPS62221679A (ja) * 1986-03-19 1987-09-29 Santen Pharmaceut Co Ltd ベンゾチアゾリン誘導体
DE4030511A1 (de) * 1990-09-27 1992-04-02 Basf Ag Hochtemperaturbestaendige, benzthiazolhaltige polyarylether
US5296486A (en) * 1991-09-24 1994-03-22 Boehringer Ingelheim Pharmaceuticals, Inc. Leukotriene biosynthesis inhibitors
NZ503491A (en) * 1997-11-10 2002-08-28 Bristol Myers Squibb Co 2-substituted amino-1,3-benzothiazole derivatives useful as protein tyrosine kinase inhibitors
WO2001074810A2 (en) * 2000-03-31 2001-10-11 Ortho Mcneil Pharmaceutical, Inc. Method for using 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles as h3 antagonists
EP1345914A1 (de) * 2000-12-22 2003-09-24 AstraZeneca AB Therapeutische verbindungen
JP2002306916A (ja) * 2001-01-26 2002-10-22 Toray Ind Inc エアフィルタユニット

Also Published As

Publication number Publication date
ZA200501098B (en) 2006-12-27
WO2004016600A1 (en) 2004-02-26
MXPA05001585A (es) 2005-04-25
EP1539723B1 (de) 2006-05-24
JP2006504672A (ja) 2006-02-09
CA2495492A1 (en) 2004-02-26
DE60305514D1 (de) 2006-06-29
AU2003248587A1 (en) 2004-03-03
CN1675189A (zh) 2005-09-28
SE0202429D0 (sv) 2002-08-14
KR20060002728A (ko) 2006-01-09
NO20051263L (no) 2005-05-12
EP1539723A1 (de) 2005-06-15
IL166412A0 (en) 2006-01-15
US20060106015A1 (en) 2006-05-18
BR0313407A (pt) 2005-07-05

Similar Documents

Publication Publication Date Title
ATE327225T1 (de) Neue verwendung von benzothiazolderivaten
DE60315674D1 (de) Neue imidazopyridine und ihre verwendung
ATE284860T1 (de) Neue verwendung von phenylheteroalkylamin- derivaten
MY157949A (en) Thioxanthine derivatives as myeloperoxidase inhibitors
NO20062136L (no) Imidazopyrazintyrosin-kinaseinhibitorer
SE0301232D0 (sv) Novel use
NO20021328L (no) Pyrazolopyrimidier som terapeutiske midler
SE0104334D0 (sv) Therapeutic agents
IL165264A (en) Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases
GB0112348D0 (en) Compounds
NO20044571L (no) Isokinolinderivater
NO20023001L (no) Substituerte piperazinderivater som MTP inhibitorer
ATE293961T1 (de) Verwendung von hydantoin und seinen derivaten gegen hypalbuminämie
SE0102058D0 (sv) New Salts II
ATE265428T1 (de) Neue verwendung von phenylheteroalkylamin- derivaten
BRPI0415546A (pt) composto, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, e de distúrbios
NO20053876D0 (no) Karbonylaminosubstituerte acylfenylurederivater, fremgangsmate for deres fremstilling samt anvendelse derav
SE0201193D0 (sv) Novel use
BR0016329A (pt) Bis-indolilmaleimidas substituìdas para inibição de proliferação de células

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties